PMID- 33571515
OWN - NLM
STAT- MEDLINE
DCOM- 20211215
LR  - 20221207
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 287
DP  - 2021 Dec 15
TI  - Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic 
      adenocarcinoma through the Wnt/beta-catenin pathway.
PG  - 119205
LID - S0024-3205(21)00190-9 [pii]
LID - 10.1016/j.lfs.2021.119205 [doi]
AB  - BACKGROUND: Elevated expression of family with sequence similarity 83 member D 
      (Fam83D) has been found in various cancers; however, its role in pancreatic 
      adenocarcinoma (PDAC) remains unclear. The current study was designed to 
      elucidate the roles of Fam83D in pancreatic cancer. METHOD: The level of Fam83D 
      was detected in PDAC tissues and adjacent no-tumorous tissues. Effects of Fam83D 
      on proliferation, glycolysis and gemcitabine (GEM) sensitivity of pancreatic 
      cancer cells were examined. RESULTS: Fam83D was overexpressed in PDAC and 
      associated with clinical stage, metastatic status and survival rates of PDAC 
      patients. Function study showed that Fam83D knockdown (KD) caused inhibited 
      proliferation, suppressed mitochondrial respiration capacity, reduced aerobic 
      glycolysis, and down-regulation of nuclear beta-catenin, proto-oncogene C-Myc, and 
      lactate dehydrogenase A (LDHA). Fam83D KD enhanced the sensitivity of PDAC cells 
      to GEM in vitro and in vivo. On the contrary, Fam83D overexpression displayed 
      reverse effects on PDAC cells. Moreover, the Wnt/beta-catenin inhibitor abolished 
      the effects of Fam83D overexpression in PDAC cells. CONCLUSIONS: the current data 
      suggest that enhanced Fam83D expression contributes to PDAC progression and the 
      development of chemoresistance through the Wnt/beta-catenin signaling.
CI  - Copyright (c) 2021. Published by Elsevier Inc.
FAU - Hua, Yong-Qiang
AU  - Hua YQ
AD  - Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 
      Dong An Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical 
      College, Fudan University, 270 Dong An Road, Shanghai 200032, PR China.
FAU - Zhang, Ke
AU  - Zhang K
AD  - Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 
      Dong An Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical 
      College, Fudan University, 270 Dong An Road, Shanghai 200032, PR China.
FAU - Sheng, Jie
AU  - Sheng J
AD  - Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 
      Dong An Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical 
      College, Fudan University, 270 Dong An Road, Shanghai 200032, PR China.
FAU - Ning, Zhou-Yu
AU  - Ning ZY
AD  - Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 
      Dong An Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical 
      College, Fudan University, 270 Dong An Road, Shanghai 200032, PR China.
FAU - Li, Ye
AU  - Li Y
AD  - Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 
      Dong An Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical 
      College, Fudan University, 270 Dong An Road, Shanghai 200032, PR China.
FAU - Shi, Wei-Dong
AU  - Shi WD
AD  - Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 
      Dong An Road, Shanghai 200032, PR China.
FAU - Liu, Lu-Ming
AU  - Liu LM
AD  - Minimally Invasive Treatment Center, Fudan University Shanghai Cancer Center, 270 
      Dong An Road, Shanghai 200032, PR China; Department of Oncology, Shanghai Medical 
      College, Fudan University, 270 Dong An Road, Shanghai 200032, PR China. 
      Electronic address: liuluming2018@163.com.
LA  - eng
PT  - Journal Article
DEP - 20210208
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (FAM83D protein, human)
RN  - 0 (Microtubule-Associated Proteins)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adenocarcinoma/drug therapy/*metabolism
MH  - Aged
MH  - Animals
MH  - Carcinogenesis/drug effects/*metabolism
MH  - Cell Cycle Proteins/*biosynthesis
MH  - Deoxycytidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Drug Resistance, Neoplasm/drug effects/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - Microtubule-Associated Proteins/*biosynthesis
MH  - Middle Aged
MH  - Pancreatic Neoplasms/drug therapy/*metabolism
MH  - Wnt Signaling Pathway/drug effects/*physiology
MH  - Xenograft Model Antitumor Assays/methods
MH  - Gemcitabine
OTO - NOTNLM
OT  - Chemoresistance
OT  - Fam83D
OT  - Glycolysis
OT  - Pancreatic adenocarcinoma
OT  - beta-Catenin
EDAT- 2021/02/12 06:00
MHDA- 2021/12/16 06:00
CRDT- 2021/02/11 20:10
PHST- 2020/12/10 00:00 [received]
PHST- 2021/01/29 00:00 [revised]
PHST- 2021/02/05 00:00 [accepted]
PHST- 2021/02/12 06:00 [pubmed]
PHST- 2021/12/16 06:00 [medline]
PHST- 2021/02/11 20:10 [entrez]
AID - S0024-3205(21)00190-9 [pii]
AID - 10.1016/j.lfs.2021.119205 [doi]
PST - ppublish
SO  - Life Sci. 2021 Dec 15;287:119205. doi: 10.1016/j.lfs.2021.119205. Epub 2021 Feb 
      8.